RE: ........askretka
You're right Al.......I took the liberty and sent the Study "Targeting amyloid-beta in glaucoma treatment" that is mentioned in the article to your hotmail. In it you will see that the researchers do compare it to Alzheimers and go on in some depth on the subject. Studies are being done on this breakthrough in Glaucoma at an ever increasing rate. The two are undoubtedly related from an Amyloid-b point of view.
Glaucoma is as well one of the many complications that arise from the Diabetic condition.
Excerpt from the Study.....
......."Amyloid-beta (Ab) is the major constituent of senile plaques in Alzheimer’s disease (AD), the formation of which, caused by
abnormal processing of amyloid precursor protein (APP), has
been involved in AD neuropathology, although the proximate
cause of the neurodegeneration responsible for cognitive impairment
is not clear (8). Ab has recently been reported to be
implicated in the development of RGC apoptosis in glaucoma,
with evidence of caspase-3-mediated abnormal APP processing
and increased expression of Ab in RGCs in experimental
glaucoma (9) and decreased vitreous Ab levels (consistent with
retinal Ab deposition) in patients with glaucoma (10). Further
evidence of a link between glaucoma and AD has emerged from
studies showing that patients with AD have RGC loss associated
with typical glaucomatous changes, such as optic neuropathy and
visual functional impairment (11–14), as is also the case in
Parkinson’s disease (15). In addition, both diseases are chronic
neurodegenerative conditions with a strong age-related incidence
(16, 17). This finding is further supported by increasing
evidence of similar pathological mechanisms involving Ab leading
to RGC loss as implicated in the brain (16, 18–20)."
Another article implicates Transitions Partner ELAN's Antibody AAB-001 in the study....... https://www.drugresearcher.com/news/ng.asp?id=78847
AZD-103 should be tried in the future as well.
GPP ALL.